Vaccines for infectious diseases

As we enter the fourth year of the Covid-19 pandemic, decisions about modifications to Covid-19 vaccines are part of the public health challenge.

The trajectory and timeline of virus evolution is hard to predict, and delays on the composition and roll-out of updated vaccines disproportionately affects low- to middle-income countries, with accessibility to boosters continuing to reflect ongoing global inequality.

Variant-specific polyvalent vaccines are not a sustainable strategy to combat emerging coronavirus threats. There must be a global push toward a universal coronavirus vaccine driven by national health systems.

GreenLight is committed to developing a next-generation Covid-19 vaccine. We are advancing our pan-sarbecovirus vaccine candidate that is potentially capable of broader coverage and predictive protection. Our goal is to produce a vaccine that will be effective against current and future Covid-19 variants, including preparing for future potential pandemics.

We have completed the design and in vitro selection of pansarbecovirus vaccine candidates and is currently evaluating them in animal studies for subsequent progression to clinical development subject to those study results.

We aim to build global, sustainable vaccine access and pandemic response readiness by developing our proprietary products or working as part of a funded collaboration.

Other diseases

We are targeting underserved diseases with a clear rationale for the use of mRNA in  vaccine development of specific disease areas. Governments, NGOs, and global alliances have prioritized preventing the next pandemic, opening potential routes for non-dilutive funding options to support research and development.

Furthermore, there is a technical advantage to mRNA manufacturing: the platform technology is sequence independent and can be adapted to new or re-emerging pathogens and scaled for clinical development within 90 days.

GreenLight is actively seeking partners to reduce direct clinical development costs and expand access to global markets.